Blue Heaven Coffee, Inc (CBIA) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBlue Heaven Coffee, Inc (CBIA) trades at $0.0001. Canopus BioPharma Incorporated operates as a pharmaceutical research company, focusing on providing products and assay methods for infectious, cancer, and addiction diseases. Sector: Communication services.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for CBIA: CBIA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Blue Heaven Coffee, Inc (CBIA) Media & Communications Profile
Canopus BioPharma Incorporated, a pharmaceutical research company in the financial services sector, focuses on providing pharmaceutical products and assay methods for infectious, cancer, and addiction diseases. Operating as a shell company, it navigates a competitive landscape with limited financial visibility, as reflected by its negative P/E ratio.
What Is the Investment Thesis for CBIA?
Canopus BioPharma Incorporated, with a market capitalization of $0.00B and a negative P/E ratio of -0.01, presents a high-risk, high-reward investment profile. The company's focus on pharmaceutical products and assay methods for infectious, cancer, and addiction diseases offers potential for significant growth if its research and development efforts yield successful and marketable products. However, the company's high beta of 9.40 indicates substantial volatility. Key catalysts include successful clinical trials and regulatory approvals. The absence of a dividend yield reflects a focus on reinvesting earnings into research and development. Investors should carefully assess the company's financial stability and the competitive landscape before considering an investment.
Based on FMP financials and quantitative analysis
CBIA Key Highlights
Market capitalization of $0.00B indicating a micro-cap company.
- Negative P/E ratio of -0.01 reflecting current losses or minimal earnings.
- Beta of 9.40 indicating high volatility compared to the market.
- No dividend yield suggesting retained earnings are reinvested in the business.
- Focus on pharmaceutical products and assay methods for infectious, cancer, and addiction diseases.
Who Are CBIA's Competitors?
CBIA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| APHD Apogee 21 Holdings, Inc. | $1.13 | -11.72% | $20.2M | — |
| KUST KUST | $4.48 | +1.36% | — | |
| DRCT Direct Digital Holdings, Inc. | $0.91 | -39.74% | — | |
| HAO Haoxi Health Technology Limited | $2.70 | 0.00% | 32 5-pillar | |
| CNET ZW Data Action Technologies Inc. | $1.60 | -13.98% | $5.87M | — |
| EDHL Everbright Digital Holding Limited Ordinary Shares | $5.23 | +3.36% | $8.71M | 33 5-pillar |
| INUV Inuvo, Inc. | $0.57 | -1.74% | $9.39M | — |
| CDLX Cardlytics, Inc. | $2.53 | -4.17% | $14.7M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CBIA's Key Strengths?
Focus on specialized pharmaceutical products.
- Research and development capabilities.
- Diverse product offerings including antivirals and oncology products.
- Potential for growth in niche markets.
What Are CBIA's Weaknesses?
Limited financial resources.
- High beta indicating significant volatility.
- Dependence on research and development success.
- Small market capitalization.
What Are the Key Risks for CBIA?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Limited financial resources and high beta indicating significant volatility.
- Regulatory hurdles and compliance costs.
- Competition from larger pharmaceutical companies.
- Risk of unsuccessful clinical trials.
- Market volatility and economic downturns.
What Are CBIA's Competitive Advantages?
- Proprietary pharmaceutical products.
- Specialized assay methods.
- Focus on niche therapeutic areas.
- Research and development capabilities.
What Does CBIA Do?
Founded in 1996 as Canopus Corporation and renamed Canopus BioPharma Incorporated in 2007, the company is based in Santa Monica, California. Canopus BioPharma focuses on developing and providing pharmaceutical products and assay methods targeting infectious, cancer, and addiction diseases. Its product offerings include antivirals, radiation protection products, oncology products, bio-barcode assays, camelidae blood products, and neutraceuticals. The company aims to address critical medical needs through research and development in these therapeutic areas. As a pharmaceutical research company, Canopus BioPharma operates within a highly regulated and competitive environment, requiring continuous innovation and strategic partnerships to sustain growth and market relevance. The company's evolution reflects its commitment to advancing pharmaceutical solutions for challenging health conditions, positioning itself as a provider of specialized products and services in the biopharmaceutical sector.
What Products and Services Does CBIA Offer?
- Provides pharmaceutical products for infectious diseases.
- Offers pharmaceutical products for cancer.
- Develops pharmaceutical products for addiction diseases.
- Supplies antivirals.
- Provides radiation protection products.
- Offers bio-barcode assays.
- Supplies camelidae blood products.
- Offers neutraceuticals.
How Does CBIA Make Money?
- Develops and researches pharmaceutical products.
- Sells pharmaceutical products to patients.
- Generates revenue through product sales.
- Focuses on niche markets like infectious, cancer, and addiction diseases.
What Industry Does CBIA Operate In?
Canopus BioPharma Incorporated operates within the shell companies industry, a segment characterized by high risk and speculative investments. The broader financial services sector is subject to regulatory scrutiny and market volatility. The pharmaceutical research market is driven by innovation and the need for new treatments for diseases like cancer and infectious diseases. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms. Canopus BioPharma's success depends on its ability to develop and commercialize its products effectively.
Who Are CBIA's Key Customers?
- Patients suffering from infectious diseases.
- Patients suffering from cancer.
- Patients suffering from addiction diseases.
- Healthcare providers.
- Research institutions.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
Blue Heaven Coffee, Inc's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Its free cash flow yield is -1.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.24 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Blue Heaven Coffee, Inc operates in the Communication Services sector. It is headquartered in Las Vegas, United States.
CBIA Financials
CBIA Latest News
No recent news available for CBIA.
CBIA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CBIA.
Price Targets
Wall Street price target analysis for CBIA.
CBIA MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CBIA; grades run from A+ (80-100) to F (below 30).
Leadership: Patrick T. Prendergast
CEO
Patrick T. Prendergast serves as the CEO of Canopus BioPharma Incorporated. Further research would be required to provide a comprehensive background on his professional experience and qualifications.
Track Record: Due to the limited information available, it is not possible to provide a detailed track record of Patrick T. Prendergast's achievements, strategic decisions, or company milestones under his leadership. Further research would be necessary to assess his performance and contributions to Canopus BioPharma Incorporated.
CBIA OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Canopus BioPharma Incorporated may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not provide regular financial disclosures, increasing the risk for investors. Investing in OTC Other stocks requires careful due diligence and an understanding of the potential risks involved compared to stocks listed on major exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low trading volume and liquidity.
- Higher price volatility.
- Potential for fraud or manipulation.
- Lack of regulatory oversight.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with OTC trading.
- Consult with a financial advisor.
- Monitor news and developments related to the company.
- Existence of a physical headquarters.
- Presence of a functional website.
- Availability of contact information.
- Engagement with investors and stakeholders.
- Compliance with basic regulatory requirements.
What Investors Ask About Blue Heaven Coffee, Inc (CBIA) — Communication Services
What do analysts say about CBIA stock?
There is no available analyst coverage for Canopus BioPharma Incorporated (CBIA) stock. The company's micro-cap status and OTC listing may contribute to the lack of analyst coverage. Investors should conduct their own thorough research and due diligence before considering an investment in CBIA.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited financial data available.
- OTC market carries inherent risks.